Business Wire

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research ...
Nasdaq

Bruker to Acquire the NanoString Business in an Asset Deal

NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healthcare Under the asset purchase ...
Business Wire

NanoString Technologies Receives Market Approval From the Australian Therapeutic Goods Administration for Its Prosigna Breast Cancer Prognostic Gene Signature Assay | Business Wire

Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilizes gene expression data weighted together ...
GEN

Aiming High: 10x, NanoString Launch Large-Scale Panels

10x Genomics has begun commercial shipments of a new 5,000–plex gene expression panel that increases plex by an order of magnitude over previous panels, a month after announcing the launch of the ...
Nasdaq

NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The ...